Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Viltolarsen
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved FDF
Sponsor : NS Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Option Care Health has been selected to participate in the limited distribution network of VILTEPSO™ (viltolarsen) for patients with Duchenne Muscular Dystrophy (“DMD”) who are amenable to exon 53 skipping therapy.
Product Name : Viltepso
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
September 02, 2020
Lead Product(s) : Viltolarsen
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Sponsor : NS Pharma
Deal Size : Undisclosed
Deal Type : Agreement